IRUS Total

The innate anti-viral effects of Azithromycin and other novel macrolides

File Description SizeFormat 
Porter-JD-2015-PhD-Thesis.pdfThesis17.01 MBAdobe PDFView/Open
Title: The innate anti-viral effects of Azithromycin and other novel macrolides
Authors: Porter, James Daniel
Item Type: Thesis or dissertation
Abstract: Asthma exacerbations are highly associated with respiratory viral infections, particularly rhinovirus (RV) infection. Currently, standard asthma medication does not include anti-viral agents despite the role viruses play. Asthmatics have also demonstrated impaired innate interferon responses to viral infection thus compounding the requirement for an anti-viral treatment. Macrolides are a class of compound often used to treat bacterial infections, Azithromycin has previously shown anti-inflammatory activity in addition to it’s potent antibiotic effects. In 2010, Gielen et al demonstrated that Azithromycin possesses anti-viral activity in an in vitro model of RV infection in human bronchial epithelial cells (HBECs). In this thesis we build on the findings of Gielen et al; we demonstrate that Azithromycin is able to augment RV-induced type I and type III interferon (IFN) and interferon stimulated gene (ISG) expression whilst reducing viral replication in HBECs cultured ex vivo from asthmatic donors. We also demonstrate that oral administration of Azithromycin is able to partially augment IFN production in a mouse model of RV infection. We elucidate a potential mechanism of action of Azithromycin’s anti-viral activity in non-asthmatic HBECs, identifying mitochondria-associated anti-viral signalling protein (MAVS) as a potential target of Azithromycin’s actions. Finally we demonstrate the development of a novel screening assay for the detection of novel macrolides with potential anti-viral activity, eventually identifying a novel macrolide (MAC5) as a compound with greater IFN augmenting ability than Azithromycin. We also identify a MAC5 analogue (MAC5K) that possesses potential anti-viral, anti-inflammatory and limited antibiotic activity.
Content Version: Open Access
Issue Date: Oct-2014
Date Awarded: Apr-2015
URI: http://hdl.handle.net/10044/1/45432
DOI: https://doi.org/10.25560/45432
Supervisor: Edwards, Michael
Hewson, Chris
Johnston, Sebastian
Sponsor/Funder: Biotechnology and Biological Sciences Research Council (Great Britain)
Pfizer Inc.
Department: National Heart & Lung Institute
Publisher: Imperial College London
Qualification Level: Doctoral
Qualification Name: Doctor of Philosophy (PhD)
Appears in Collections:National Heart and Lung Institute PhD theses

Unless otherwise indicated, items in Spiral are protected by copyright and are licensed under a Creative Commons Attribution NonCommercial NoDerivatives License.

Creative Commons